407 related articles for article (PubMed ID: 2985703)
1. Cyclic AMP-dependent protein kinase in Molt 4b lymphoblasts: identification by photoaffinity labeling and activation in intact cells by vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI).
O'Dorisio MS; Wood CL; Wenger GD; Vassalo LM
J Immunol; 1985 Jun; 134(6):4078-86. PubMed ID: 2985703
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
[TBL] [Abstract][Full Text] [Related]
3. VIP modulates intracellular calcium oscillations in human lymphoblasts.
Anton PA; Shanahan F; Sun XP; Diehl D; Kodner A; Mayer EA
Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):429-46. PubMed ID: 8227970
[TBL] [Abstract][Full Text] [Related]
4. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
5. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
6. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
7. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide receptor/adenylate cyclase system: differences between agonist- and protein kinase C-mediated desensitization and further evidence for receptor internalization.
Turner JT; Bollinger DW; Toews ML
J Pharmacol Exp Ther; 1988 Nov; 247(2):417-23. PubMed ID: 2846820
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and neuropeptide modulation of the immune response.
O'Dorisio MS; Wood CL; O'Dorisio TM
J Immunol; 1985 Aug; 135(2 Suppl):792s-796s. PubMed ID: 2861233
[TBL] [Abstract][Full Text] [Related]
10. Cyclic AMP formation in C6 glioma cells: effect of PACAP and VIP in early and late passages.
Sokolowska P; Nowak JZ
Ann N Y Acad Sci; 2006 Jul; 1070():566-9. PubMed ID: 16888226
[TBL] [Abstract][Full Text] [Related]
11. Cyclic AMP formation in chicken brain: effect of vasoactive intestinal peptide, peptide histidine-isoleucine (PHI), and some PHI-related peptides.
Dejda A; Matczak I; Wiktorowska-Owczarek A; Nowak JZ
Pol J Pharmacol; 2003; 55(5):747-51. PubMed ID: 14704471
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of a functional receptor for vasoactive intestinal polypeptide on Molt 4b T lymphoblasts.
Beed EA; O'Dorisio MS; O'Dorisio TM; Gaginella TS
Regul Pept; 1983 Apr; 6(1):1-12. PubMed ID: 6306732
[TBL] [Abstract][Full Text] [Related]
13. PACAP, VIP, and PHI: effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures.
Dejda A; Jozwiak-Bebenista M; Nowak JZ
Ann N Y Acad Sci; 2006 Jul; 1070():220-5. PubMed ID: 16888170
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes.
Mittag TW; Tormay A; Podos SM
J Pharmacol Exp Ther; 1987 Apr; 241(1):230-5. PubMed ID: 3033201
[TBL] [Abstract][Full Text] [Related]
15. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
18. Identification of vasoactive intestinal peptide receptor subtypes in the lacrimal gland and their signal-transducing components.
Hodges RR; Zoukhri D; Sergheraert C; Zieske JD; Dartt DA
Invest Ophthalmol Vis Sci; 1997 Mar; 38(3):610-9. PubMed ID: 9071214
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
20. Effects of forskolin on adenylate cyclase activity and amylase secretion in the rat exocrine pancreas.
Dehaye JP; Gillard M; Poloczek P; Stievenart M; Winand J; Christophe J
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(3):269-80. PubMed ID: 2410466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
